- The Tiger's Prey
- Posts
- Lifecore Biomedical, Inc.
My sixth write-up is now available for download!
During the last conference call, an unidentified analyst asked LFCR’s management whether double-digit growth is a reasonable expectation beyond FY25. The question went unanswered. The truth is that such growth is achievable even with just the existing late-phase development pipeline and conservative time to commercialization assumptions. A better question would have been how much growth could accelerate if any of the catalysts outlined in this write-up were to materialize. Let’s dive in!
Grab your copy of the report by clicking the “Download” button below, and download the accompanying model from the button that follows. At the end, you’ll also find a list of LFCR write-ups and industry conferences the company will participate in.
Subscribe to The Tiger's Prey to unlock the rest.
Become a paying subscriber of The Tiger's Prey to get access to this post and other subscriber-only content.
Already a paying subscriber? Sign In.
A subscription gets you:
- • Investment write-ups (+ institutional-grade models), published at least 20 times annually and at least once monthly
- • Monthly performance reviews, featuring write-up and aggregate performance with brief commentary
- • Weekly updates on 23 (and counting) idea generation screens, published every Sunday at 13:00 ET